Clinical trials: Chest--Diseases
In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
The purpose of this phase I/Ib study was to determine the safety profile of NIZ985 (new formulation), and if it could be safely combined with spartalizumab or tislelizumab and to determine the appropriate dose and schedule for…
- Trial name
- NCT04261439
- Testing
- NIZ985, Spartalizumab, Tislelizumab
- Where
- 9 sites in United States, Belgium and 5 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Androgen Independent Prostate Cancer (AIPC), Non Small Cell Lung Cancer (NSCLC)
Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004
The purpose of this study is to monitor the safety of continued DN-101 and docetaxel treatment for subjects previously enrolled in DN101-002 (ASCENT) or DN101-004 (NSCLC) Studies.
- Trial name
- NCT00285675
- Testing
- DN-101 (calcitriol) - Drug
- Where
- 13 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Novacea
Non-small Cell Lung Cancer
Tissue Eosinophils in Non-Small Cell Lung Cancer (the TEN Study)
The primary objective is to describe eosinophil infiltration in resected (early stage) NSCLC. Secondary objectives are: to investigate the correlation of T-Eos and B-Eos in the aforementioned patient population; to investigate…
- Trial name
- TEN (NCT05537701)
- Where
- Belgium
- Volunteers
- 316 people
- Sponsor
- Centre Hospitalier Universitaire de Liege
Lung Diseases
Image - Navigated Resection of Lung Nodules
This is an open label study lung nodules that are either cancer or non-cancer and who are eligible for surgical resection. Patients will undergo their surgery with the help of the Lung Resection Marker Locator Kit which will…
- Trial name
- NCT04702165
- Testing
- lung resection with Lung Resection Marker Locator Kit
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Navigation Sciences, Inc.
Lung Adenocarcinoma, Stage III Lung Cancer
Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study
This is a prospective, single-arm, multicenter Phase II clinical study. It aims to evaluate the efficacy and safety of Firmonertinib combined with chemotherapy in patients with unresectable Stage III lung adenocarcinoma harboring…
- Conditions
- Lung Adenocarcinoma, Stage III Lung Cancer, EGFR Positive Non-small Cell Lung Cancer
- Trial name
- NCT07878871
- Testing
- Firmonertinib, Platinum-based chemotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Hunan Province Tumor Hospital
Carcinoma, Non-Small -Cell Lung
Analysis of Brain Metastasis in Patients With Lung Cancer
This study will examine patients with non-small cell lung cancer metastasis, that is, the distant spreading of tumors to the brain, and compare them with patients without brain metastasis.
- Trial name
- NCT00071344
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Small Cell Lung Cancer
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
This study will test the safety of the study drug, DS-3201b, given in combination with irinotecan to people who have recurrent small cell lung cancer (SCLC).
- Trial name
- NCT03879798
- Testing
- DS-3201b, irinotecan
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Fatigue, Stress
The U.K. Embryologist Fatigue Study
The purpose of the study is to determine physical and mental health issues of U.K. embryologists related to their occupational characteristics, and how workplace fatigue and burnout may affect their quality of life, cynicism…
- Conditions
- Fatigue, Stress, Burnout, Professional, Musculoskeletal Pain
- Trial name
- FUSE-UK (NCT05708963)
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- TMRW Life Sciences
Non Small Cell Lung Cancer
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS
This Phase II study consists of 2 parts: 1) pre-screening phase and 2) treatment phase. The pre-screening phase will investigate the presence of HRAS mutations in subjects with a histologically or cytologically confirmed…
- Trial name
- NCT03496766
- Testing
- Tipifarnib
- Where
- 30 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Spanish Lung Cancer Group
Lung Neoplasm, Small Cell Carcinoma
Hypofractionated Radiotherapy for Small Cell Lung Cancer
Current treatments for limited stage small cell lung cancer have poor cure rates. The addition of chest radiation to chemotherapy improves cure rates, but these cancers still come back in the chest 30-50% of the time.
- Trial name
- NCT00469222
- Testing
- hypofractionated external beam
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- AHS Cancer Control Alberta
Non-small Cell Lung Cancer
Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy
The purpose of this study is to determine if Pemetrexed plus Carboplatin plus Bevacizumab plus Enzastaurin, followed by maintenance Bevacizumab plus Enzastaurin can extend survival time without disease progression in the…
- Trial name
- NCT00533429
- Testing
- enzastaurin, pemetrexed, carboplatin
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, Non Small Cell Lung Cancer
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
COPE is a biology driven protocol with 2 independent, multicentric, two-arm non-comparative randomized (2:1) phase II trials in 2 distinct populations: colorectal cancer patients and non-small-lung cancer patients.
- Trial name
- COPE (NCT04258137)
- Testing
- Liquid biopsy
- Where
- 6 sites in France
- Volunteers
- 332 people
- Sponsor
- Institut Bergonié
Small Cell Lung Cancer
Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC
CLINATEZO cohort will evaluate overall survival, real world progression-free survival, best response and duration of treatment in patients with advanced, metastatic Small Cell Lung Cancer (SCLC) who received atezolizumab combined…
- Trial name
- CLINATEZO (NCT04920981)
- Testing
- atezolizumab
- Where
- 2 sites in France
- Volunteers
- 518 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Coronary Artery Disease, Chest Pain
Imaging Studies With GE C-Hawk Gamma Camera Compared to Routine Clinical Exam
Comparison study of myocardial perfusion SPECT imaging with current clinical use camera and new camera.
- Trial name
- NCT00256581
- Testing
- Additional rest and stress image sets on new camera
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Wisconsin, Madison
Pain, Anxiety
Virtual Reality During the Removal of Chest Drains in Critically-ill Patients
Appropriate pain and anxiety management of critically-ill patients during bedside procedures remains a big challenge. Clinical Practice Guidelines recommend preemptive analgesia or non-pharmacological interventions, such as…
- Trial name
- NCT05332119
- Testing
- VR glasses, Control group
- Where
- Spain
- Volunteers
- 98 people
- Sponsor
- Gemma Via Clavero
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
- Conditions
- Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors
- Trial name
- NCT07148128
- Testing
- WEF-001
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Auricula Biosciences Inc.
Pleural Effusion
Detection of Pleural Effusion by Internal Thoracic Impedance Method
Early detection of pleural effusion (PLE) would improve the treatment. However, preclinical detection of pleural effusion is often not possible.
- Trial name
- NCT01601444
- Testing
- Pletysmograph
- Volunteers
- 100 people
- Sponsor
- Michal Roll PhD,MBA
Advanced Solid Tumors, Non-small Cell Lung Cancer
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
This is the first human study to use X-396 (ensartinib), a drug being developed for treatment of advanced cancers. The initial purpose of the study is to determine the largest amount of X-396 that can be safely given to humans…
- Trial name
- NCT01625234
- Testing
- Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib)
- Where
- 14 sites in United States
- Volunteers
- 131 people
- Sponsor
- Xcovery Holdings, Inc.
Esophageal Neoplasms, Head and Neck Neoplasms
Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.
The purpose of this study is to observe the safety and effectiveness of the add-on of intraluminal brachytherapy with BRAXX esophageal brachytherapy applicator after definitive CCRT in patients with thoracic esophageal cancer.
- Conditions
- Esophageal Neoplasms, Head and Neck Neoplasms, Gastrointestinal Neoplasms, Digestive System Diseases
- Trial name
- NCT06365866
- Testing
- "BRAXX" Esophageal Brachytherapy Applicator., Add-on of intraluminal brachytherapy
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Interstitial Lung Disease, Lung Cancer
Assessment of Exhaled Breath Condensate Hydrogen Peroxide (EBC H2O2) as Measured Using a New Device (Inflammacheck™) in Patients With Interstitial Lung Disease, Lung Cancer and Healthy Volunteers.
A cross-sectional study of EBC H2O2 levels, as measured by a novel device, 'Inflammacheck™', and other markers of disease severity in patients with ILD and Lung Cancer.
- Trial name
- EXHALE 1B (NCT04061356)
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Portsmouth Hospitals NHS Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.